
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics demonstrates a strategic focus on financial prudence by executing a workforce reduction and reallocating resources toward the development of EO-1022, a HER3-targeting antibody-drug conjugate, which may enhance future growth potential. The company aims to streamline operations and conserve funds in response to challenging market conditions, reflecting a disciplined financial approach. Moreover, the adjustments made to financial models, including a planned revenue recognition for EO-1022 starting in 2031, highlight a forward-looking strategy that positions the company for long-term success while navigating its clinical-stage landscape.
Bears say
Enliven Therapeutics has faced a significant setback with the discontinuation of the Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy in its Phase 1 study, raising concerns about the viability of this asset within its pipeline. Despite the treatment's tolerable safety profile, the reduced efficacy diminishes its attractiveness for further investment, leading to skepticism about the company's growth potential. Additionally, the drastic reduction in the 12-month price target from $6.00 to $1.00 reflects a lack of confidence in Enliven's ability to deliver successful product candidates and generate substantial returns in the near future.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares